Protein Technologies
Scientific Library
Therapeutics
Synthesis and antimicrobial activity of 2-fluorophenyl-4,6-disubstituted [1,3,5]triazines (PDF)
Mona Saleh, Shaun Abbott, Valérie Perron, Caroline Lauzon, Christopher Penney and Boulos Zacharie
Bioorganic and Medicinal Chemistry Letters 2010, 20, 945-949
2,4,6-Trisubstituted Triazines as Protein A Mimetics for the Treatment of Autoimmune Diseases (PDF)
Boulos Zacharie, Shaun D. Abbott, Jean-Francois Bienvenu, Alan D. Cameron, Jose Cloutier, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Caroline Lauzon, Nancie Moreau, Valerie Perron, Nicole Wilb,
Michel Asselin, Andre Doucet, Marie-Eve Fafard, Dannyck Gaudreau, Brigitte Grouix, Francois Sarra-Bournet,
Natalie St-Amant, Lyne Gagnon, and Christopher L. Penney
Journal of Medicinal Chemistry 2010 (in press)
An Efficient Kilogram-Scale Synthesis of N,N-Bis(4,6-disubstituted 1,3,5-triazin-2-yl)-4-aminophenetylamine (PDF)
Jean-Simon Duceppe, Valerie Perron, Josee Cloutier, Christopher Penney, and Boulos Zacharie
Organic Process Research & Development 2009, 13, 1156–116
Oral treatment of PBI-1402 prevents doxorubicin-induced nephrotoxicity in mice (PDF)
Lyne Gagnon, Brigitte Grouix, Nathalie Julien, Mouna Lagraoui, Andre Doucet, Kathy Hince, François Leblond, Vincent Pichette, Christopher Penney, Pierre Laurin
American Society of Nephrology 42nd Annual Meeting
Oral treatment with PBI-1402 increases hemoglobin, hematocrit and red blood cell formation in 5/6 nephrectomized (NX) rats, a model mimicking human end-stage renal disease (ESRD) (PDF)
Lyne Gagnon, François A. Leblond, Brigitte Grouix, Mouna Lagraoui and Vincent Pichette
American Society of Nephrology 42nd Annual Meeting
Oral treatment with PBI-1402 improves glomerular filtration rate by reducing tubulo-interstitial fibrosis and sclerosis in 5/6 nephrectomized (NX) rats (PDF) François A. Lebond, Lyne Gagnon, Brigitte Grouix, Mouna Lagraoui, Andre Douet, François Sarra-Bournet, Lilianne Geerts, Christopher Penney, Pierre Laurin, Vincent Pichette
American Society of Nephrology 42nd Annual Meeting
A simple and efficient large-scale synthesis of metal salts of medium-chain fatty acids (PDF)
Boulos Zacharie, Abdallah Ezitouni, Jean-Simon Duceppe, Christopher Penney Organic Process Research & Development Vol 13, No 3, 2009 581-583
2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases (PDF)
Zacharie B, Fortin D, Wilb N, Bienvenu JF, AsselinM, Grouix B, Penney C Bioorg. Med. Chem. Lett. 19 (2009) 242–246
A Method for the Selective Protection of Aromatic Amines in the Presence of Aliphatic Amines (PDF)
Valérie Perron, Shaun Abbott, Nancie Moreau, Devin Lee, Christopher Penney, Boulos Zacharie
SYNTHESIS 2009, No. 2, pp 0283–0289
PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia (PDF)
European Hematology Association
13th Congress, June 12-15, 2008
PBI-1308 inhibits inflammation and cancer cell proliferation through inhibition of NF-kB (PDF)
American Association of Cancer Research Annual Meeting 2008, April 12-16, 2008
Anticancer effect of PBI-0110 in combination with gemcitabine in intradermal and orthotopic pancreatic cancer (PDF)
American Association of Cancer Research Annual Meeting 2008, April 12-16, 2008
Antitumor activity of PBI-1737 in xenograft human prostate (PC-3) cancer by inhibition of cell adhesion and migration (PDF)
American Association of Cancer Research Annual Meeting 2008, April 12-16, 2008
Triazine Derivatives as Protein A Mimetcs for the Treatment of Autoimmune Disease (PDF)
1st International Conference on Drug Design & Discovery, February 7, 2008. Presentation by Dr. Boulos Zacharie.
Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393 (PDF)
Allam M, Julien N, Zacharie B, Penney C, Gagnon L.
Clin Immunol. 2007 Dec;125(3):318-27.
Oral treatment with PBI-1402 increases hemoglobin level and red blood cell count: A novel approach to treating chemotherapy-induced anemia (PDF)
American Society of Hematology 49th Annual Meeting
1,3,5-Triazine derivatives with improved solubility for the treatment of inflammatory diseases (PDF)
American Chemical Society 234th National Meeting & Exposition
In vitro and in vivo modulatory effect of PBI-1393 on LPSinduced
neutrophil activation and inflammatory response (PDF)
The 8th World Congress on. Inflammation, June 16–20, 2007
1,3,5-Triazine Derivatives as Protein A Mimetics for the Treatment of Autoimmune Diseases (PDF)
American Chemical Society 232nd National Meeting & Exposition
Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cylcophosphamide (PDF)
Kadhim, S., Penney, C., Lagraoui, M., Heibein, J., Attardo, G., Zacharie, B., Connolly, T., Gagnon, L.
International Journal of Immunopharmacology 22, 2000, pp. 659-671
Synthesis and Activity of 6-substituted Purine Linker Amino Acid Immunostimulants (PDF)
Zacharie, B., Gagnon, L., Attardo, G., Connolly, T.P., St-Denis, Y., Penney, Christopher L.
Journal of Medicial Chemistry, Volume 40, Number 18, 2000, pp. 2883-2894.
Protein Technologies
vCJD: An Ongoing Threat to Public Health and its Management
(PDF)
Dr. Robert Rohwer, Patient Safety Conference 2010, London, England
An Improved Performance Adsorbent for the Downstream Processing of Serum Albumin and Related Fusion Proteins (PDF)
Bastiaan Lobbezoo, Ben Galarza, Jim Morritt, Chloe Booth, Jennifer Walden and Dev Baines,
BioProcess International, Raleigh, NC.
A Synthetic Ligand Affinity Adsorbent for Capture and Purification of Genetically Engineered Antibody Fragment Therapeutics (PDF)
Sharon Williams, Bastiaan Lobbezoo, Michelle Stobbart, Helen Kirkman and Steve Burton, BioProcess International, Raleigh, NC
Characterization of a resin-nonwoven separation medium for removal of prions from complex suspension (PDF)
M.O.Hergistad, P.V.Gurgel, R.G.Carbonell, Prion2009 Conference Chalcidice, Greece
Biochemical quality of the pharmaceutically licensed plasma OctaplasLG(R) after implementation of a novel prion protein (PrPSC) removal technology and reduction of the solvent/detergent (S/D) process time (PDF)
A.Heger, T.-E.Svae, A.Neisser-Svae, S.Jordan, M.Behizad & J.Romisch
Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG(R) (PDF)
A.Neisser-Svae, A.Bailey, L.Gregori, A.Heger, S.Jordan, M.Behizad, H.Reichl, J.Romisch & T.-E.Svae,
In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma™ P-CAPT prion-reduction filter (PDF)
C.V. Murphy, E. Eakins, J. Fagan, H. Croxon & W.G. Murphy, Transfusion Medicine, 2009, 19, 109-116
Prion Infectivity Removal from Human Plasma and Plasma Products Using Affinity Ligands (PDF)
L. Gregori, B. Lambert,P.V. Gurgel, J. Lathrop,M. Behizad, S. Jordan, and R. Rohwer,
Plasma Product Biotechnology Meeting 2009Menorca, Spain
The potential for low cost manufacturing of safe plasma products (PDF – Read-only), PPB09 Menorca, Spain - John Curling, Christopher Bryant, Tom Chen, Timothy Hayes, ProMetic BioTherapeutics, Inc., Neil Goss, Further Options Ltd.,Andrew Sinclair, Janice Lim, BioPharm Services Ltd., Mahesh Prashad, Sartorius Stedim Biotech
Alternatives to Protein A capture (PDF) Dev Baines, Sharon Williams, Steve Burton, EuroBiotechNews Nº 3-4, Volume 8, 2009
Determination of Specificity and Capacity for the P-Capt(TM) Prion Removal Filter (PDF) L. Gregori, J.T. Lathrop, P.V. Gurgel, N. Lescoutra, R.G. Rohwer ISBT 2009
Hybrid Particle-Nonwoven Membrane separation Medium for Removal of Pathogenic Contaminants from Red Blood Cell Concentrate (PDF) M.O. Herigstad, P.V. Gurgel, R.G. Carbonnell
Depletion of high abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column (PDF) Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC, Strancar A. J Chromatogr A. 2009; 1216:2689-2694
Development of a Device for Reduction of Prion Infectivity from
Red Blood Cell Concentrate (PDF)
P.V. Gurgel, L. Gregori, J. Lathrop, R.G. Carbonell, R. Rohwer, S. Burton
PrPCanada 2009
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study (PDF)
Simon Mead, Mark Poulter, James Uphill, John Beck, Jerome Whitfield, Thomas EF Webb, Tracy Campbell, Gary Adamson, Pelagia Deriziotis, Sarah J Tabrizi, Holger Hummerich, Claudio Verzilli, Michael P Alpers, John C Whittaker, John Collinge
Lancet Neural 2009;8:57-66
Specificity and capacity of the P-Capt(R) filter for prion protein and prion infectivity (PDF)
Prion 2008
Reduction of prion from red cells, plasma and plasma products using specific affinity ligands (PDF)
Prion 2008
Removal of prion infectivity from plasma-derived products (PDF)
Recovery of Biological Products 13 Conference
Prion Safety and Transfusion Plasma Abstract Book (PDF)
30th International Congress of the International Society of Blood Transfusion,
June 7-12, 2008,
Presentation by Octapharma
The introduction of a novel prion protein (PrPSc) removal technology for the pharmaceutically licensed plasma Octaplas® (PDF)
30th International Congress of the International Society of Blood Transfusion,
June 7-12, 2008,
Presentation by Octapharma
Biochemical quality of the pharmaceutically licensed plasma Octaplas® after implementation of a novel prion protein (PrPSc) removal technology (PDF)
30th International Congress of the International Society of Blood Transfusion,
June 7-12, 2008,
Presentation by Octapharma
Development of a device for prion reduction based on affinity ligand (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. Patrick Gurgel
Managing the risks from blood associated TSE infectivity with prion affinity ligands (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. R. Rohwer
Process Chromatography – Five Decades of Innovation (PDF)
Curling J.M.
Biopharm International, February 2007
Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands (PDF)
Luisa Gregori, Brian C. Lambert, Patrick V. Gurgel, Liliana Gheorghiu, Peter Edwardson, Julia T. Lathrop, Claudia MacAuley, Ruben G. Carbonell, Steven J. Burton, David Hammond, and Robert G. Rohwer
Transfusion, Volume 46, pp. 1152-1161, July 2006
Reduction in infectivity of endogenous transmissible
spongiform encephalopathies present in blood by
adsorption to selective affinity resins (PDF)
Luisa Gregori, Patrick V Gurgel, Julia T Lathrop, Peter Edwardson, Brian C Lambert, Ruben G Carbonell, Steven J Burton, David J Hammond, Robert
G Rohwer
Lancet 2006; 368: 2232–36
Prion reduction filters (PDF)
Marc L Turner,
Edinburgh Blood Transfusion Centre, Royal Infi rmary of Edinburgh
Lancet 2006; Vol 368 December 23/30
The Plasma Fractionation Industry. New Opportunities To Move Forward? (PDF)
Curling, J.M. and Bryant, C.
BioProcess International, March 2005
New Challenges for Biopharmaceutical Process Development (PDF)
Curling, J.M.
Biotechnology Focus, February 2005
Affinity chromatography – from textile dyes to synthetic ligands by design. Part 2
Curling, J. M.
BioPharm Intl. 17, No. 8, 60-66, August 2004.
Affinity chromatography – from textile dyes to synthetic ligands by design. Part 1
Curling, J. M.
BioPharm Intl. 17, No. 7, 34-42, July 2004.
Integrating new technology into blood plasma fractionation
Curling, J. M.
BioPharm 15, No. 9, 16-25, September 2002.
Affinity Chromatography
Smiley, L., and Curling, J.M.
Genetic Engineering News, November 15, 2001.
Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins
Behizad, B., Curling, J.M.
Biopharm, Vol 13 No 7 pp. 42–46., September 2000.
Development and Commercialization of Biomimetics
Burton, J.
Link, Collaborative Research, 2000.
Regulatory Aspects of Column chromatography in Biopharmaceutical Manufacturing
Behizad, M., Baines, D.
Biopharm Vol 11 No 5, May 1998.
Design, Synthesis, and Application of a Protein A Mimetic
Li, Rongxiu., Dowd, V., Stewart, D.J., Burton, S.J., Lowe, C.R.
Nature Biotechnology, Vol 16, pp. 190–195, February 1998.